- Price changes for etanercept and adalimumab
PHARMAC has created significant savings in the market for two of New Zealand’s most costly medicines. Adalimumab (Humira) and etanercept (Enbrel) are biologic medicines used to treat a number of autoimmune and immune-mediated conditions, including rheumatoid arthritis. With current annual expenditure on TNF inhibitors in excess of $80 million, there was significant potential to secure lower valuable savings for these medicines.
PHARMAC has promoted competition in this market to successfully generate savings of more than $20 million over 5 years.
Promoting competition is a central philosophy to PHARMAC’s activity and this was key in achieving these price reductions. The savings can be reinvested into funding of other medicines.
Last updated: 10 December 2015